Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H16N4O.ClH |
Molecular Weight | 256.732 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CNC(=N)NC(=O)NC1=C(C)C=CC=C1C
InChI
InChIKey=INMBONSHXVMDSX-UHFFFAOYSA-N
InChI=1S/C11H16N4O.ClH/c1-7-5-4-6-8(2)9(7)14-11(16)15-10(12)13-3;/h4-6H,1-3H3,(H4,12,13,14,15,16);1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C11H16N4O |
Molecular Weight | 220.2709 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Lidamidine, also known as WHR-1142A and Lidaral, is an alpha2-adrenergic receptor agonist that inhibits intestinal secretion, reduces intestinal transit, and inhibits smooth muscle contraction. Lidamidine hydrochloride is used to treat diarrhoea and other gastrointestinal disorders. Lidamidine’s intestinal antisecretory effects are
mediated through the activation of peripheral alpha-2 adrenoceptors. Lidamidine crosses
the blood brain barrier poorly and is therefore devoid of the centrally mediated alpha-2
effects that have limited the use of other alpha-2 adrenoceptor agonists in the intestinal
tract.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Lidarral Approved UseLidamidine Hydrochloride. Lidamidine is an alpha2-adrenergic receptor stimulant used as the hydrochloride for the management of diarrhoea and other gastrointestinal disorders. |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10975022
Lidamidine HCL (4 mg) or placebo was taken orally t.i.d. with food. Lidamidine decreased the augmented mechanical response to food, reduced rectal sensitivity, and relieved symptoms of patients with irritable bowel syndrome.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6121738
The effects of clonidine and lidamidine on ion transport in the intestine of the rabbit were determined. In the ileum both clonidine (10(-6) M) and lidamidine (10(-3) M) (a) decreased the short circuit current (-1.9 +/- 0.3 and -2.0 +/- 0.4 muEq/h . cm2, respectively) and potential difference; (b) increased net sodium absorption (2.0 +/- 0.6 and 1.8 +/- 0.4 muEq/h . cm2) and chloride absorption (3.4 +/- 0.5 and 3.4 +/- 0.6 muEq/h . cm2); and (c) increased tissue conductance (8.7 +/- 1.7 and 10.0 +/- 1.6 mmho/cm2).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:14:36 GMT 2023
by
admin
on
Fri Dec 15 15:14:36 GMT 2023
|
Record UNII |
3Q1Q4QJV3V
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C266
Created by
admin on Fri Dec 15 15:14:36 GMT 2023 , Edited by admin on Fri Dec 15 15:14:36 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000128598
Created by
admin on Fri Dec 15 15:14:36 GMT 2023 , Edited by admin on Fri Dec 15 15:14:36 GMT 2023
|
PRIMARY | |||
|
m6804
Created by
admin on Fri Dec 15 15:14:36 GMT 2023 , Edited by admin on Fri Dec 15 15:14:36 GMT 2023
|
PRIMARY | Merck Index | ||
|
3Q1Q4QJV3V
Created by
admin on Fri Dec 15 15:14:36 GMT 2023 , Edited by admin on Fri Dec 15 15:14:36 GMT 2023
|
PRIMARY | |||
|
CHEMBL448416
Created by
admin on Fri Dec 15 15:14:36 GMT 2023 , Edited by admin on Fri Dec 15 15:14:36 GMT 2023
|
PRIMARY | |||
|
DTXSID10983557
Created by
admin on Fri Dec 15 15:14:36 GMT 2023 , Edited by admin on Fri Dec 15 15:14:36 GMT 2023
|
PRIMARY | |||
|
SUB35843
Created by
admin on Fri Dec 15 15:14:36 GMT 2023 , Edited by admin on Fri Dec 15 15:14:36 GMT 2023
|
PRIMARY | |||
|
47509
Created by
admin on Fri Dec 15 15:14:36 GMT 2023 , Edited by admin on Fri Dec 15 15:14:36 GMT 2023
|
PRIMARY | |||
|
65009-35-0
Created by
admin on Fri Dec 15 15:14:36 GMT 2023 , Edited by admin on Fri Dec 15 15:14:36 GMT 2023
|
PRIMARY | |||
|
265-307-6
Created by
admin on Fri Dec 15 15:14:36 GMT 2023 , Edited by admin on Fri Dec 15 15:14:36 GMT 2023
|
PRIMARY | |||
|
C82241
Created by
admin on Fri Dec 15 15:14:36 GMT 2023 , Edited by admin on Fri Dec 15 15:14:36 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |